Russia to significantly expand geography of its drug export

3 February 2025

Russia plans to significantly expand the geography of the export of its drugs this year, paying attention both to emerging nations and developed countries, reports The Pharma Letter’s local correspondent.

At present, Russia supplies about 45,000 tons of drugs annually to more than 160 countries. According to the Russian Ministry of Industry and Trade, in 2024 exports amounted to 180 billion roubles ($18 billion) and, as part of state plans, this figure should grow significantly this year.

Rustem Muratov, general director of Binnopharm Group, one of Russia’s leading drugmakers said in an interview with the Russian Rossiyskay Gazeta business paper, at present there is a high demand for Russian generics in other countries. Also, there is the ever-growing demand for Russian vaccines, particular those against flu, measles, polio and other infections. Finally, Russia also exports a wide range of cardiology drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics